|Bid||7.63 x 1400|
|Ask||7.64 x 3100|
|Day's range||7.52 - 8.08|
|52-week range||0.25 - 18.77|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||04 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||7.90|
The World Health Organization is expected to soon grant emergency use listing for COVID-19 vaccine Covaxin. While the vaccine was developed by Bharat Biotech, Ocugen (NASDAQ: OCGN) has the rights to market Covaxin in the U.S. and in Canada. In this Motley Fool Live video recorded on Sept. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Ocugen stock is worthy of another look by investors if Covaxin receives EUL.
Ocugen (NASDAQ: OCGN) shares were flying high earlier this year. The company signed a deal with India's Bharat Biotech for co-commercialization rights to its coronavirus vaccine candidate in the U.S. The Bharat product was close to market. Since then, Ocugen learned it wouldn't win the right to sell the vaccine in the U.S. as soon as it had hoped.
Investors are nervous about a Food and Drug Administration advisory panel meeting and optimistic about a World Health Organization decision.